Gene therapy in status epilepticus

@article{Walker2013GeneTI,
  title={Gene therapy in status epilepticus},
  author={Matthew C. Walker and Stephanie Schorge and Dimitri Michael Kullmann and Robert C. Wykes and Joost H. Heeroma and Laura Mantoan},
  journal={Epilepsia},
  year={2013},
  volume={54}
}
Gene therapy in human disease has expanded rapidly in recent years with the development of safer and more effective viral vectors, and presents a novel approach to the treatment of epilepsy. Studies in animals models have demonstrated that overexpression of inhibitory peptides can modify seizure threshold, prevent the development of epilepsy, and modify established epilepsy. More recently there has been a flurry of studies using optogenetics in which light‐activated channels expressed in… Expand
Viral Vectors and Other Modulatory Biologics
TLDR
The current viral and nonviral vector systems characterized for therapeutic development to combat neurological disorders are discussed, with special attention to those studies that have been advanced to human clinical trials. Expand
Changing channels in pain and epilepsy: Exploiting ion channel gene therapy for disorders of neuronal hyperexcitability
TLDR
A review of the key experimental successes and challenges facing a number of viral gene therapy approaches explored to manipulate the expression of the most direct modulators of excitability in chronic pain and epilepsy. Expand
Investigational Treatments for Status Epileptics
TLDR
This chapter focuses on antiseizure medications in clinical trials, the somewhat more remote prospect of gene therapy, and transcranial magnetic stimulation. Expand
Concise Review: Prospects of Bone Marrow Mononuclear Cells and Mesenchymal Stem Cells for Treating Status Epilepticus and Chronic Epilepsy
TLDR
This concise review evaluates the current knowledge and outlook pertaining to MNC and MSC therapies for SE and chronic epilepsy and discusses the behavior of these cells in animal models of SE and their efficacy to restrain neurodegeneration, inflammation, and epilepsy. Expand
Antiepileptic Drug Discovery
TLDR
Psychological approaches in rodents support that neuroinfl ammation is involved in modulating seizure susceptibility, neuronal damage, and other neurological disorders associated with epilepsy. Expand
Tumor‐related epilepsy and epilepsy surgery
TLDR
There are relatively few recent literature resources on TRE that provide neurologists, neurosurgeons, epileptologists, and oncologists with an up‐to‐date, state‐of‐the‐art review of the field in all of its important aspects. Expand
Epilepsy priorities in Europe: A report of the ILAE‐IBE Epilepsy Advocacy Europe Task Force
TLDR
Recommendations that emerged at ERF2013 about how to strengthen epilepsy research, reduce the treatment gap, and reduce the burden and stigma associated with epilepsy are provided. Expand
Genetic Engineering: Tinkering with the Human Body
TLDR
Science fiction sometimes includes a human character who is biologically superior in at least one distinct way to a conventional example of H. sapiens, due to natural processes, such as the slow changes produced by evolution. Expand
Épilepsie partielle continue : étude vidéo-EEG et évolution à partir d'une série de 28 patients
TLDR
Cette etude est la plus grande serie de cas d’EPC tous documentes par VEEG, ainsi que le traitement etiologique, which permis de reduire les insuffisances liees au caractere retrospectif de cette andude, en confirmant le diagnostic d”EPC et en ecartant les diagnostics differentiels. Expand
Linking Molecular, Electrical And Anatomical Properties Of Human Epileptic Brain
LINKING THE MOLECULAR, ELECTRICAL AND ANATOMICAL PROPERTIES OF HUMAN EPILEPTIC BRAIN
...
1
2
...

References

SHOWING 1-10 OF 24 REFERENCES
Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy.
TLDR
The data show that this gene therapy strategy decreases spontaneous seizures and suppresses their progression in chronic epileptic rats, thus representing a promising new therapeutic strategy. Expand
Adenosine augmentation therapies (AATs) for epilepsy: Prospect of cell and gene therapies
TLDR
To meet the therapeutic goal of focal adenosine augmentation, genetic disruption of theadenosine metabolizing enzyme adenosinergic neuromodulation in rodent and human cells was used as a molecular strategy to induceAdenosine release from cellular brain implants, which demonstrated antiepileptic and neuroprotective properties. Expand
Optogenetic control of epileptiform activity
TLDR
It is proved a principle, that selective hyperpolarization of principal cortical neurons by NpHR is sufficient to curtail paroxysmal activity in transduced neurons and can inhibit stimulation train-induced bursting in hippocampal organotypic slice cultures, which represents a model tissue of pharmacoresistant epilepsy. Expand
Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion
Seizure disorders present an attractive gene therapy target, particularly because viral vectors such as adeno-associated virus (AAV) and lentivirus can stably transduce neurons. When we targeted theExpand
Gene Therapy for Human Genetic Disease?
TLDR
A sustained effort is proposed to be made to formulate a complete set of ethicoscientific criteria to guide the development and clinical application of gene therapy techniques, which could go a long way toward ensuring that gene therapy is used in humans only in those instances where it will prove beneficial, and toward preventing its misuse through premature application. Expand
Acute down‐regulation of adenosine A1 receptor activity in status epilepticus
TLDR
The present study examines the effectiveness of focal drug delivery in a model of limbic SE and describes, for the first time, alterations in A1R signaling during prolonged seizures that may contribute to the progression from self‐terminating seizures to self‐sustaining SE (SSSE). Expand
Status epilepticus may be caused by loss of adenosine anticonvulsant mechanisms
TLDR
The results of this study suggest that loss of GABAergic inhibition only has a minor role in status epilepticus development in models, suggesting that impairment of G-protein-linked receptors is involved in the development of status epileptus. Expand
On-demand optogenetic control of spontaneous seizures in temporal lobe epilepsy
TLDR
It is demonstrated that spontaneous temporal lobe seizures can be detected and terminated by modulating specific cell populations in a spatially restricted manner and a clinical approach built on these principles may overcome many of the side-effects of currently available treatment options. Expand
The controversial role of adenoviral-derived vectors in gene therapy programs: where do we stand?
  • G. Romano
  • Biology, Medicine
  • Drug news & perspectives
  • 2006
TLDR
Adenoviral-mediated gene transfer is a promising tool for cancer therapy and for genetic immunization programs against infectious diseases, provided that host immune responses are carefully controlled. Expand
Enhanced tonic GABAA inhibition in typical absence epilepsy
TLDR
It is shown that extrasynaptic GABAA receptor–dependent 'tonic' inhibition is increased in thalamocortical neurons from diverse genetic and pharmacological models of absence seizures, identifying an apparently common cellular pathology in typical absence seizures that may have epileptogenic importance and highlight potential therapeutic targets for the treatment of absence epilepsy. Expand
...
1
2
3
...